- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05442190
Aktuelt SGX302 for mild til moderat psoriasis
Fase 2-studie som evaluerer SGX302 (syntetisk hypericin) i behandling av mild til moderat psoriasis
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
San Diego, California, Forente stater, 92123
- Therapeutics Clinical Research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
- Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
- Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.
Exclusion Criteria:
- Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
- Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
- Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
- Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort 1 - SGX302 Ointment (0.25 % Hypericin)
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a gradual escalation of light therapy up to 25 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Andre navn:
|
|
Eksperimentell: Cohort 2 - SGX302 Ointment (0.25 % Hypericin)
SGX302 (0.25 % hypericin) ointment will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a faster escalation of light therapy up to 25 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Andre navn:
|
|
Eksperimentell: Cohort 3 - SGX302 Gel (0.25 % Hypericin)
SGX302 (0.25 % hypericin) gel will be applied to lesions and treated with visible light 24±6 hours later starting at 5 J/cm^2 with a faster escalation of light therapy up to 40 J/cm^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 18 weeks. |
SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Patients That Achieve a 0 or 1 Score Using the 5-point Investigator's Global Assessment Scale
Tidsramme: 18 weeks
|
The percentage of patients in each treatment group that achieve a 0 or 1 score (Clear or Almost Clear) evaluation using the 5-point Investigator's Global Assessment (IGA) scale. The 5-point IGA scale:
|
18 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
SkinDex-29 Score
Tidsramme: Baseline, End of Treatment (Week 18)
|
The SkinDex-29 is a validated quality of life questionnaire that measures the effects of skin diseases on a person's life. It is a series of 30 questions assessing the participant's opinion of the impact of their disease on their life in the previous 4 weeks. Answers are scored from 1 (never), 2 (rarely), 3 (sometimes), 4 (often) to 5 (all the time) and are summed to get a total score. The minimum score possible is 30 and the maximum score possible is 150. A lower score means a better outcome. |
Baseline, End of Treatment (Week 18)
|
|
Dermatology Life Quality Index Score
Tidsramme: Baseline, End of Treatment (Week 18)
|
The Dermatology Life Quality Index was developed as a general quality of life instrument to measure the impact of chronic skin disease on patients. The aim of the questionnaire is to measure how much the participant's skin problems affected their life over the past week. The questionnaire contains 10 questions with responses ranging from 0 (not at all), 1 (a little), 2 (a lot) to 3 (very much) that are summed to get a total score. The minimum score possible is 0 and the maximum score possible is 30. A lower score means a better outcome. |
Baseline, End of Treatment (Week 18)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HPN-PSR-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .